We will continue to pursue our primary goals of elucidating the structural and conformational features required of opioid ligands for binding with high affinity and high selectivity to specific opioid receptors and of using this information for the development of better (more potent, more selective, more stable, etc.) opioid analogs of potential therapeutic value. As in the past, our focus will be on the delta opioid receptor, however we propose to investigate an exciting initial lead that may help define important similarities and differences between delta and mu receptor requirements. Our general approach will combine analog design and synthesis, in vitro pharmacological testing, and conformational analysis. Two structural series, both containing analogs conformationally restricted by side chain to side chain cyclization via disulfide bonds, and both of which we have previously described will be investigated. The first of these is a pentapeptide series in which the lead compound is the highly delta selective DPDPE, while the second series is a further conformationally restricted tetrapeptide series, in which the lead analog JOM-13 (Tyr-D-Cys-Phe-D- Pen) also displays high delta selectivity. Analogs planned, most of which incorporate further conformational constraints, will identify specific structural and conformational features of the delta pharmacophore and will address the possibility that the two series may interact with different subsites of the delta receptor. Pharmacological screening of new analogs will be via assays for mu, delta, and kappa opioid receptor binding, to be done in our labs, and by standard MVD and GPI and smooth muscle bioassays, done via a Consortium arrangement with Prof. Frank Porreca of the University of Arizona. Conformational analyses will employ both experimental and computational methods. Modern NMR methods will be the primary experimental tool and will be complemented by distance geometry and molecular mechanics calculations. Our multidisciplinary, integrated approach provides us with all the tools necessary to pursue our goals in a reasonable and efficient manner.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA003910-07
Application #
3208728
Study Section
Special Emphasis Panel (SRCD (11))
Project Start
1985-08-01
Project End
1997-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Pharmacy
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Anand, Jessica P; Kochan, Kelsey E; Nastase, Anthony F et al. (2018) In vivo effects of ?-opioid receptor agonist/?-opioid receptor antagonist peptidomimetics following acute and repeated administration. Br J Pharmacol 175:2013-2027
Anand, Jessica P; Boyer, Brett T; Mosberg, Henry I et al. (2016) The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice. Psychopharmacology (Berl) 233:2479-87
Harland, Aubrie A; Bender, Aaron M; Griggs, Nicholas W et al. (2016) Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy ?-Opioid Receptor (MOR)/?-Opioid Receptor (DOR) Ligands. J Med Chem 59:4985-98
Bender, Aaron M; Griggs, Nicholas W; Anand, Jessica P et al. (2015) Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy ? opioid receptor/? opioid receptor ligands. ACS Chem Neurosci 6:1428-35
Geng, Jie; Pogozheva, Irina D; Mosberg, Henry I et al. (2015) Use of Functional Polymorphisms To Elucidate the Peptide Binding Site of TAP Complexes. J Immunol 195:3436-48
Harland, Aubrie A; Yeomans, Larisa; Griggs, Nicholas W et al. (2015) Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy ?-Opioid Receptor (MOR) Agonists/?-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. J Med Chem 58:8952-69
Anand, Jessica P; Porter-Barrus, Vanessa R; Waldschmidt, Helen V et al. (2014) Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues. Biopolymers 102:107-14
Mosberg, Henry I; Yeomans, Larisa; Anand, Jessica P et al. (2014) Development of a bioavailable ? opioid receptor (MOPr) agonist, ? opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance. J Med Chem 57:3148-53
Bender, Aaron M; Clark, Mary J; Agius, Michael P et al. (2014) Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity ? opioid receptor (MOR) agonist/? opioid receptor (DOR) antagonist ligands. Bioorg Med Chem Lett 24:548-51
Pogozheva, Irina D; Mosberg, Henry I; Lomize, Andrei L (2014) Life at the border: adaptation of proteins to anisotropic membrane environment. Protein Sci 23:1165-96

Showing the most recent 10 out of 83 publications